Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common diabetes drug protect hearts in kidney disease?

NCT ID NCT05719714

First seen Apr 15, 2026 · Last updated May 21, 2026 · Updated 5 times

Summary

This study looks at how dapagliflozin, a drug used for diabetes, affects heart and lung function in people with chronic kidney disease and early signs of heart failure. Researchers will measure heart strain, oxygen use during exercise, and blood markers. About 60 adults with moderate kidney disease will take the drug alongside their usual care to see if it improves heart and metabolic health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60607, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.